Immunovant, Inc. (IMVT) SEC Filings

Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl sold 1,327 shares of common stock on October 7, 2026, at a weighted-average price of $32.06 per share; the shares were sold in multiple transactions at prices ranging from $31.58 to $32.30 per share. Immunovant required the sale to cover tax withholding obligations tied to RSU vesting and settlement, so it was not discretionary. After the sale, Van Tuyl directly held 175,218 shares. No Rule 10b5-1 plan is reported.

Immunovant, Inc. (IMVT) Chief Operating Officer Melanie Gloria sold 2,241 shares of common stock on October 7, 2026, at a weighted average price of $32.06 per share. The shares were sold to cover tax withholding tied to 4,761 RSUs that vested October 1, 2026; Immunovant required the sell-to-cover transaction, which was not discretionary. Gloria directly held 217,060 shares afterward.

Immunovant, Inc. Chief Executive Officer Eric Venker reported that 92,187 capped value appreciation rights (CVARs) settled into common stock on October 1, 2026, after the service, performance, knock-in and $14.46 hurdle-price requirements were satisfied. The settlement formula capped the common stock’s fair market value at $16.76 per share. Venker also reported a disposition to the issuer of 85,886 common shares at $33.65 per share and sold 3,506 shares at $34.11 on October 2 to cover tax withholding. The issuer required the sell-to-cover transaction, which was not discretionary; 921,875 CVARs remained after settlement.

Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl sold 2,846 shares of common stock on September 23, 2026, at a weighted average price of $36.36 per share, leaving him with 176,545 shares held directly. The sale was a sell-to-cover transaction mandated by the issuer to fund tax withholding tied to the vesting and settlement of 6,872 restricted stock units on September 16, 2026; the transaction was not discretionary. No Rule 10b5-1 plan is reported.

Immunovant, Inc. (IMVT) reported the results of its 2026 Annual Meeting of Stockholders held on September 2, 2026, with approximately 96% of common and Series A preferred shares entitled to vote represented in person or by proxy. Stockholders elected Jacob Bauer, Douglas Hughes and Robert Susman as directors until the 2027 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending March 31, 2027, and approved, on a non-binding advisory basis, the compensation of Immunovant’s named executive officers as disclosed in the proxy statement.

Immunovant, Inc. (IMVT) director Atul Pande exercised fully vested stock options to acquire 1,500 shares of common stock at an exercise price of $8.43 per share and on the same date sold 1,500 shares at $43.27 per share. Following the option exercise, he holds 65,181 options directly, and a separate indirect holding shows 20,000 shares held by a trust. The reported transactions were effected pursuant to a Rule 10b5-1 Plan adopted on December 26, 2025.

Immunovant, Inc. (IMVT) reported that Chief Operating Officer Gloria Melanie sold 3,056 shares of common stock on August 20, 2026, at a weighted average price of $44.16 per share. The shares were sold to cover tax withholding obligations arising from the vesting and settlement of previously granted RSUs under a mandated “sell to cover” arrangement, and are described as not being a discretionary transaction by the officer. Following this sale, she holds 219,301 shares of Immunovant common stock directly.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin report their beneficial ownership of Immunovant, Inc. common stock on an amended Schedule 13G. As of June 30, 2026, they collectively beneficially owned 9,341,151 shares of common stock, representing 4.55% of the class.

The filing states that all 9,341,151 shares are subject to shared voting and shared dispositive power, with no sole voting or dispositive power reported for any of the filers. The percentage ownership is calculated using 205,308,917 Immunovant common shares outstanding as of May 14, 2026, as disclosed in Immunovant’s Form 10-K. The report is filed jointly, and Deep Track Capital, LP is identified as the relevant entity for which David Kroin may be considered a control person.

Immunovant, Inc., a clinical-stage immunology company focused on anti-FcRn antibody IMVT-1402, reported a net loss of $153.2 million for the quarter ended June 30, 2026, compared with $120.6 million a year earlier. Research and development expenses rose by $41.4 million to $142.6 million, driven by expanded IMVT-1402 programs in endocrine, neurological, rheumatology and dermatology diseases, while general and administrative expenses declined by $8.3 million to $17.7 million.

Cash and cash equivalents were $797.8 million, with operating activities using $124.4 million in cash in the quarter. Based on its current operating plan, the company expects this cash to fund operating expenses and capital expenditures to the potential commercial launch of IMVT-1402 in Graves’ disease, though it acknowledges a need to raise additional capital to fully implement its broader business plan.

The development pipeline centers on IMVT-1402 in six autoimmune indications, including potentially registrational trials in Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, CIDP and Sjögren’s disease, plus a proof-of-concept study in cutaneous lupus erythematosus. In a difficult-to-treat rheumatoid arthritis trial, open-label Period 1 Week 16 results showed ACR20/50/70 response rates of 72.7%/54.5%/35.8% in a heavily pretreated population, with no new drug-related safety signals observed, and further data are expected in the second half of calendar 2026.